Analysts Set Health Catalyst, Inc. (NASDAQ:HCAT) PT at $12.10

Shares of Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eleven analysts that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $12.10.

A number of equities analysts have recently weighed in on the company. Guggenheim raised Health Catalyst from a "neutral" rating to a "buy" rating and set a $14.00 price objective for the company in a research note on Friday, January 26th. Barclays assumed coverage on Health Catalyst in a research note on Wednesday, January 3rd. They set an "overweight" rating and a $14.00 price target for the company. KeyCorp reissued a "sector weight" rating on shares of Health Catalyst in a research note on Wednesday. Cantor Fitzgerald reissued an "overweight" rating and set a $16.00 price target on shares of Health Catalyst in a research note on Wednesday. Finally, Canaccord Genuity Group dropped their price target on Health Catalyst from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Friday, February 23rd.

Health Catalyst Stock Performance

Health Catalyst stock traded down $0.31 during mid-day trading on Friday, reaching $6.09. 370,935 shares of the stock traded hands, compared to its average volume of 552,776. The stock has a market capitalization of $356.63 million, a PE ratio of -2.90 and a beta of 1.29. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.42 and a quick ratio of 4.42. Health Catalyst has a 12-month low of $5.99 and a 12-month high of $14.37. The business's 50-day moving average is $8.21 and its 200-day moving average is $8.54.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.06. Health Catalyst had a negative return on equity of 12.19% and a negative net margin of 39.92%. The company had revenue of $75.08 million during the quarter, compared to analysts' expectations of $73.67 million. As a group, sell-side analysts predict that Health Catalyst will post -0.47 EPS for the current fiscal year.

Insider Transactions at Health Catalyst

In related news, insider Linda Llewelyn sold 3,163 shares of the firm's stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $10.83, for a total value of $34,255.29. Following the completion of the transaction, the insider now owns 68,048 shares in the company, valued at approximately $736,959.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.70% of the company's stock.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently modified their holdings of HCAT. Nepsis Inc. boosted its holdings in Health Catalyst by 20.5% in the 4th quarter. Nepsis Inc. now owns 1,091,932 shares of the company's stock worth $10,111,000 after buying an additional 186,128 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Health Catalyst by 124.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 854,896 shares of the company's stock worth $8,652,000 after buying an additional 473,323 shares during the last quarter. MQS Management LLC acquired a new stake in Health Catalyst in the 3rd quarter worth about $116,000. Vanguard Group Inc. boosted its holdings in Health Catalyst by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 6,441,707 shares of the company's stock worth $65,190,000 after buying an additional 78,823 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in Health Catalyst by 10.4% in the 3rd quarter. American Century Companies Inc. now owns 657,552 shares of the company's stock worth $6,654,000 after buying an additional 62,010 shares during the last quarter. Hedge funds and other institutional investors own 85.00% of the company's stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.